Active Surveillance for Low-risk Papillary Thyroid Carcinoma

Shijie Yang^{1

2}, Meijuan Tan¹, Xiequn Xu¹

Affiliations

¹ Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Comment

Shijie Yang et al. JAMA Oncol. 2023.

. 2023 May 1;9(5):722-723.

doi: 10.1001/jamaoncol.2023.0003.

Shijie Yang^{1

2}, Meijuan Tan¹, Xiequn Xu¹

¹ Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

No abstract available

Comment in

Active Surveillance for Low-risk Papillary Thyroid Carcinoma-Reply.
Ho AS, Sacks WL, Zumsteg ZS. Ho AS, et al. JAMA Oncol. 2023 May 1;9(5):722-723. doi: 10.1001/jamaoncol.2023.0006. JAMA Oncol. 2023. PMID: 36862392 No abstract available.

Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial.
Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, Mallen-St Clair J, Chen MM, Vasquez M, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZS, Braunstein GD, Sacks WL. Ho AS, et al. JAMA Oncol. 2022 Sep 15;8(11):1588-96. doi: 10.1001/jamaoncol.2022.3875. Online ahead of print. JAMA Oncol. 2022. PMID: 36107411 Free PMC article.